Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Expression Pathology Inc.. (12/9/10). "Press Release: Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology. Two Leading Companies Offer Clients Integrated Services for Digital Pathology and Quantitative Mass-spec

Organisations Organisation Expression Pathology Inc. (EPI)
  Today OncoPlex Diagnostics (OncoPlexDx)
  Group OncoPlex Diagnostics (OncoPlexDx)
  Organisation 2 Flagship Biosciences Inc.
Products Product Liquid Tissue Array
  Product 2 digital pathology services
Index term Index term Expression Pathology–Flagship Biosciences: tissue proteomics, 201012– collab offering Liquid Tissue SRM assays with digital pathology services
Persons Person Eitner, Casey (Expression Pathology 200806 CEO)
  Person 2 Bloom, John (Flagship Biosciences 201012 Board Member)
     


Expression Pathology, the leading provider of FFPE tissue-based proteomics, and Flagship Biosciences, the leading digital pathology services firm, announce a service partnership that enables tissue translational biomarker development, validation and application in support of drug development.

Many pharmaceutical, biotech and academic clinical research organizations require robust targeted assays to translate and validate their biomarker discovery efforts with respect to protein expression in tissue. Customers of Expression Pathology and Flagship can now leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass-spec tissue analysis and digital pathology. Flagship's pathology expertise to ensure the right tissue or sub anatomic organelle is analyzed combined with Expression Pathology's expertise in multiplex tissue proteomic assays using FFPE tissue offers an exciting and comprehensive tissue analysis service to customers.

"Expression Pathology's unique and proprietary Liquid Tissue® SRM assays for quantitative analyses of proteins in FFPE tissue are opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions" said Casey Eitner, President and CEO of Expression Pathology Inc.

"Translational and personalized medicine today requires better integration of the enabling technologies these platforms and new generation of service organizations provide," said John Bloom, a member of Flagship's Board of Directors and a well-known leader in translational medicine. "This novel partnership is prototypic of what is required to meet the needs of drug development and patient care in this dynamic area of applied biomarker science."

Expression Pathology Inc. (EPI) is a private biotechnology company leading the development of innovative assays to measure functional tissue proteins in research and diagnostic applications.

Flagship Biosciences LLC is a pathologist-owned contract research organization that delivers quantitative pathology and tissue-based companion diagnostics in drug and device development.

   
Record changed: 2016-03-19

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for OncoPlex Diagnostics (OncoPlexDx)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top